FINNENCE ▪ THE WIRE FILE
THE WIRE · № 82003
News▲ Bullish
New composite outcomes data show patients treated with Lilly's Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease at one year
KINDNews
DIRECTION▲ Bullish
SOURCES1
ENTITIES2
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Composite outcomes data for Omvoh in UC and Crohn's strengthens Lilly's immunology franchise versus competitors.
Lilly immunology data supports franchise expansion
CATALYST TO WATCH
Regulatory submissions or label updates
MAIN RISK
Composite endpoints may not sway payers
FULL DISPATCH
In LUCENT-2, more than one in four (27.7%) Omvoh-treated patients with ulcerative colitis achieved comprehensive disease control, a novel composite outcome defined by simultaneous symptomatic, endoscopic and histologic remission, biomarker normalization and no corticosteroid use In...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDEli Lilly · LLY
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
North Carolina groups ask attorney general to review the Atrium-WakeMed merger2026-10-15 11:46 UTC
North Carolina groups ask attorney general to review the Atrium-WakeMed merger2026-10-15 11:46 UTC
→CORRELATIONshares Healthcare
Iambic Therapeutics sets $16 IPO price, targets $150 million raise2026-10-15 11:55 UTC
Iambic Therapeutics sets $16 IPO price, targets $150 million raise2026-10-15 11:55 UTC
→CORRELATIONshares Healthcare
Odacova Health Unveils Nine-Year Canine Longevity Study at ALOS 2026, Charting a New Path to Extend Pet Healthspan2026-10-15 12:32 UTC
Odacova Health Unveils Nine-Year Canine Longevity Study at ALOS 2026, Charting a New Path to Extend Pet Healthspan2026-10-15 12:32 UTC
←CORRELATIONshares Healthcare
OrbiMed Raises $3 Billion Across Global and Asia Private Equity Funds2026-10-15 11:30 UTC
OrbiMed Raises $3 Billion Across Global and Asia Private Equity Funds2026-10-15 11:30 UTC
←CORRELATIONshares Healthcare
Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health2026-10-15 11:30 UTC
Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health2026-10-15 11:30 UTC
←CORRELATIONshares Healthcare
New Phase 3 trial: Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3) — Merck Sharp & Dohme LLC2026-10-15 12:00 UTC
New Phase 3 trial: Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3) — Merck Sharp & Dohme LLC2026-10-15 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.